How long can I take Gilotrif (afatinib) for?
Gilotrif (afatinib) is a prescription medication used to help stop or slow the spread of cancer in people with epidermal growth factor receptor (EGFR)-positive non-small cell lung cancer (NSCLC). Patients tend to take Gilotrif for about 11 to 13 months, although the length of treatment varies from person to person.
How long you can take Gilotrif for depends on how well it’s working for you and the side effects it causes. Usually it’s taken until your cancer starts to progress or you can no longer tolerate the side effects.
In clinical trials, the median amount of time patients remained on Gilotrif was about 11 to 13 months. This is similar to the results from a study done in a real-world setting, which found that the median duration of time patients remained on Gilotrif for the first-line treatment of their NSCLC was 12.1 months. Patients who were male, had chronic obstructive pulmonary disease (COPD) or chronic kidney disease tended to take Gilotrif for a shorter period of time.
Patients who took Gilotrif in a real-world setting as a second-line treatment for NSCLC (when other treatments had failed) took it for about 8 months. However, in a phase III trial in patients using it as a second-line treatment, the Gilotrif-treated patients who experienced a longer-term benefit from the drug received Gilotrif for a median of 19 months.
References
- Lim J, Samuelsen C, Golembesky A, Shrestha S, Wang L, Griebsch I. Duration of treatment among patients prescribed afatinib or erlotinib as first-line therapy for EGFR mutation-positive non-small-cell lung cancer in the USA. Future Oncol. 2019;15(13):1493-1504. doi:10.2217/fon-2019-0052.
- Wu YL, Sequist LV, Tan EH, et al. Afatinib as First-line Treatment of Older Patients With EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Subgroup Analyses of the LUX-Lung 3, LUX-Lung 6, and LUX-Lung 7 Trials. Clin Lung Cancer. 2018;19(4):e465-e479. doi:10.1016/j.cllc.2018.03.009.
- Kato T, Yoshioka H, Okamoto I, et al. Afatinib versus cisplatin plus pemetrexed in Japanese patients with advanced non-small cell lung cancer harboring activating EGFR mutations: Subgroup analysis of LUX-Lung 3. Cancer Sci. 2015;106(9):1202-1211. doi:10.1111/cas.12723.
- Goss GD, Cobo M, Lu S, et al. Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung: Final analysis of the randomised phase 3 LUX-Lung 8 trial. EClinicalMedicine. 2021;37:100940. Published 2021 Jun 18. doi:10.1016/j.eclinm.2021.100940.
Read next
Is Gilotrif (afatinib) a chemotherapy drug?
Gilotrif (afatinib) is a chemotherapy drug used to treat non-small-cell lung cancer (NSCLC) that is caused by an abnormal epidermal growth factor receptor (EGFR) gene or genes. It is is a small molecule drug and EGFR tyrosine kinase inhibitor.
Gilotrif is a type of targeted chemotherapy because it specifically targets and blocks EGFR. Targeted chemotherapy drugs are different from traditional chemotherapy agents which attack all dividing cells, damaging healthy cells as well as cancerous ones. Continue reading
How does Gilotrif (afatinib) work?
Gilotrif (afatinib) is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor used in the treatment of non-small cell lung cancer (NSCLC). It is used to treat NSCLC that is EGFR-positive, meaning that it is caused by an abnormal EGFR gene. Gilotrif works by targeting and irreversibly blocking EGFR.
Gilotrif helps to stop or slow the spread of NSCLC. Continue reading
Is small cell or non-small cell lung cancer worse?
Generally, small cell lung cancer (SCLC) is worse than non-small cell lung cancer (NSCLC). SCLC accounts for about 10-15% of people who have lung cancer and is the most aggressive form of lung cancer. SCLC usually starts in the breathing tubes (bronchi), and although the cells are small, they grow very quickly and create large tumors. Early on in the course of the disease, there are rarely any symptoms. If caught early (limited-stage disease) 20-25% of people can be potentially cured. Extensive SCLC is more difficult to treat. Continue reading
Related medical questions
- Is non-small cell lung cancer hereditary?
- How aggressive is non-small cell lung cancer?
- Does smoking cause non-small cell lung cancer?
- What type of lung cancer is Vizimpro used to treat?
- What type of cancer is Tecentriq used to treat?
- How long does it take for Keytruda to work?
- Why give Taxol (Paxel) before carboplatin?
- What is the difference between Opdivo and Keytruda?
- Pembrolizumab vs. nivolumab: How do they compare?
- What is Paxel called in the USA?
- How effective is Lumakras, what's the survival rate?
- What is the difference between Mvasi and Avastin?
- Are there cost-saving programs for Tecentriq?
- How effective is Tabrecta?
- How does erlotinib work (mechanism of action)?
- How effective is atezolizumab (Tecentriq)?
- Opdivo vs Opdivo Qvantig: What is the Difference?
- Is atezolizumab (Tecentriq) a chemotherapy or immunotherapy drug?
- Will Tabrecta cure lung cancer?
- How long do you take Alecensa for?
- How effective is Alecensa for ALK-positive NSCLC?
- Is Tabrecta a chemotherapy drug?
- How does Retevmo work?
- What is the mechanism of action for Alecensa (alectinib)?
- Can Tarceva (erlotinib) cure lung cancer?
- How does pemetrexed work?
- How do Exkivity and Rybrevant compare for NSCLC?
- How does Rybrevant work?
Drug information
Related support groups
- Gilotrif (3 questions, 4 members)
- Afatinib (3 questions, 5 members)
- Non-Small Cell Lung Cancer (53 questions, 73 members)